April 13, 2004 Committee Secretary Joint Standing Committee on Treaties Department of House of Representatives Parliament House CANBERRA ACT 2600

Dear Madam / Sir,


I have particular concerns about the impact of the AUSTUS-FTA on our Pharmaceutical Benefits Scheme (PBS).

The following submission is based at talks I have given on this subject at public meetings held in both Melbourne and Sydney.

Please note that this material has been prepared in my capacity as a concerned Australian citizen; it does not necessarily represent the views of any organisation with which I am affiliated.


Sincerely,


Dr. Ken Harvey, MB BS, FRCPA, MASM. Board Member, Therapeutic Guidelines Ltd.; Council Member, Australian Consumers Association; Senior Lecturer, School of Public Health, La Trobe University; http://users.bigpond.net.au/medreach/











Influencing drug policy



(P)

Payments to research and policy organisations, 'to generate a higher volume of messages from credible sources' sympathetic to the pharmaceutical industry: US \$2 m.

 Funding a standing network of economists to speak against US drug price controls: US \$1 m.
Changing the Canadian Health Care System:

PhRMA

Expenditure Millions 2003–2004


US \$1 m. (Pear 2003)


• During the last Presidential election, the American pharmaceutical industry contributed \$14 million to George Bush's campaign.

Over the last ten years pharmaceutical indust



- Over the last ten years, the pharmaceutical industry has been by far the most profitable in the US.
- The pharmaceutical giants spend 2-3 times more on marketing and administration as on R&D; their profits are about twice R&D costs.
- For example, last year GlaxoSmithKline spent 37 percent of its revenues on marketing and administration, 14 percent on R&D, while making a 28 percent profit.









Where does PhRMA money go?

eigh

It's not surprising that the FTA became a PBS negotiating battleground. The question is, "Who won?"



PEE


Mark Vaile said, "The PBS, in particular the price and listing arrangements that ensure Australians access to quality, affordable medicines, remains intact' (Vaile 2004).


Given that


background

- US Senator Jon Kyl said, "a breakthrough made with respect to pharmaceuticals". (Kyl 2004).
- *Medicines Australia* said, "The triumph is in the text" (Haynes 2004).











Annex 2C: Medicines Working Group

N.B. Focus

 The Parties hereby establish a Medicines Working Group.

PES


Charles II


- The objective of the Working Group shall be to promote discussion and mutual understanding of issues relating to this Annex (except those issues overed in paragraph 4), including the importance of pharmaceutical research and development to continued improvement of healthcare outcomes.
- The Working Group shall comprise officials from federal government agencies responsible for federal healthcare programs and other appropriate federal government officials.


19


Ironically, the public health goal of equitable access to affordable drugs is not on the agenda (if it was the US could have much to learn from Australia). DoHA argues that the working group is similar

- DoHA argues that the working group is similar to others set up for other industries affected by the FTA; that the group isn't a policy-making body and will only serve as a discussion forum.
- Once again, US officials appear to have a different view of the likely impact of working group than do Australian officials.
- US Senator Jon Kyl, "...I know there is much more work that needs to be done in further discussions with the Australians"









DES-**FTA-PBS:** Summary dictioned and • Australian negotiators believe they have, "held the line" on the PBS. The Americans disagree! ٠ They can't both be right! • Clearly the FTA opens up • additional pressure points on the PBS that are likely to ultimately US Trade Representative Zoellick & result in higher drug prices, less Australian Trade Minister Vaile generic competition and more pharmaceutical promotion.





